Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.32 USD | -0.39% | -7.81% | -32.78% |
Mar. 28 | Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target | MT |
Mar. 13 | Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.78% | 4.11B | |
-1.82% | 41.35B | |
+41.48% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Immunovant : Receives $200 Million Investment from Roivant Sciences